Figure 7

Efficacy of CXCR3 blockade on peritoneal progression of p53(-/-) ID8 EOC and the survival of C57BL6 mice. Mice (Control group, n = 5; CXCR3 mAb group, n = 4) were inoculated ip with ID8 cells and treated ip with vehicle or CXCR3 mAb for 5 weeks. The ACs of mice were measured to determine the percentage increase in AC. The body weight of mice was measured to monitor treatment toxicity (A). The Kaplan–Meier survival curve and median survival time of mice were determined using a 50% increase in AC as the endpoint (B). Mice (n = 5) were inoculated ip with ID8 cells and treated ip with vehicle, AMG487, bevacizumab (Bev), or both in combination for 5 weeks. Bev group, n = 4. The ACs of mice were measured to determine the percentage increase in AC. The body weight of mice was measured to monitor treatment toxicities. Data are means ± SD.*, p < 0.05; **, p < 0.01 (C). The Kaplan–Meier survival curve and median survival time of mice were determined using a 50% increase in AC as the endpoint. p values are shown (D). Mice (n = 5 and n = 3 from two experiments) inoculated ip with ID8 cells were treated with vehicle or AMG487 for 5 weeks. When mice reached the survival endpoint, tumor ascites was obtained and CD3 + T cells were isolated, stained, and analyzed by a flow cytometer to determine the percentages of activated CD8 + T cells and FOXP3 + CD4 + Tregs in total CD3 + T cells. Each dot represents the value of an individual mouse. Means and SD of all mice in each treatment group, and p values are shown (E).